

TATFAR was created in 2009 to address the urgent threat of antimicrobial resistance (AMR). TATFAR's technical experts from Canada, the European Union (EU), Norway, and the United States (U.S.) collaborate and share best practices to strengthen domestic and global efforts in the fight against antimicrobial resistance (AMR).

## Key Focus Areas



Improve antibiotic use in humans and animals



Prevent infections and their spread



Strengthen the drug pipeline

## Success

Working together the past five-year implementation period, TATFAR member agencies have continued valuable technical engagement to address AMR in the following actions:

- Published an online report titled [Data for Action: Using Available Data Sources at the Country Level to Track Antibiotic Use](#).
- Published resources summarizing data sources to quantify antibiotic use in human health care and on antibiotic use targets in TATFAR partner countries. This resource is for public health agencies, governments, and other stakeholders interested in assessing antibiotic use.
- Led and coordinated annual observances to raise awareness about appropriate use of antibiotics and AMR.
- Worked on three collaborative manuscripts (pending publication) addressing point-prevalence survey (PPS) methods and PPS data use for hospitals and for long-term care facilities/nursing homes
- Published papers summarizing [economic incentives](#) for antibacterial drug development.
- Transatlantic communication on research and development of new pharmaceuticals, new diagnostic tests, and clinical trials.

## Moving Forward

TATFAR partners will:

- Continue exchange of information and collaboration around key topics such as appropriate antibiotic use, emerging and concerning resistance trends, and development of antibacterial agents.
- Collaborate on new areas including wastewater surveillance of AMR, modeling strategies, communications, and policy.
- Prioritize a One Health focus.
- Identify ways to improve communication on AMR and help amplify TATFAR partner messaging through the Taskforce.
- Consider impacts of COVID-19 on AMR.